Fluoxetine for Visual Recovery After Ischemic Stroke "FLUORESCE"
Recruiting
Phase 2 Results N/ASummary of Purpose
The purpose of this study is to determine whether fluoxetine, a selective serotonin reuptake inhibitor commonly used for depression, enhances visual recovery after an acute ischemic stroke.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 16 July 2017.
1 May 2016 | 1 Apr 2016 | 1 Jun 2020 | 1 Jun 2020 | 1 Jul 2017 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
- Bogachan Sahin, MD, PhD
bogachan_sahin@urmc.rochester.edu (585) 275-2530
- Ann M Leonhardt, NP
ann_leonhardt@urmc.rochester.edu (585) 275-2530
View Trial Locations
Recruitment
- Enrollment: 40
- Gender: All
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country